MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F19%3A00078237" target="_blank" >RIV/00209805:_____/19:00078237 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10398630 RIV/00216208:11140/19:10398630 RIV/00179906:_____/19:10398630 RIV/00669806:_____/19:10398630 a 2 dalších

Výsledek na webu

<a href="http://cgp.iiarjournals.org/content/16/5/353.long" target="_blank" >http://cgp.iiarjournals.org/content/16/5/353.long</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/cgp.20140" target="_blank" >10.21873/cgp.20140</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Popis výsledku v původním jazyce

Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p&lt;0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.

Název v anglickém jazyce

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Popis výsledku anglicky

Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p&lt;0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

—

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer genomics &amp; proteomics

ISSN

1109-6535

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

7

Strana od-do

353-359

Kód UT WoS článku

000483944900005

EID výsledku v databázi Scopus

2-s2.0-85071763471